WHO invites makers of mpox tests for emergency review in push for rapid access
Adds details and background throughout
Aug 29 (Reuters) -The World Health Organization on Thursday sought to speed up theaccess to diagnostic tests for mpox by askingmanufacturers to submit their products for an emergencyreview.
The agency has been in discussions with manufacturers about the need for effective diagnostics, particularly in low-income groups.
To expand access to diagnostic services urgently, the WHOhas called for submissions from manufacturers forEmergency Use Listing that would allow it toapprove medical products such as vaccines, tests and treatments.
The process aims to assist countries to procure the critically needed products such as tests through UN agencies and other partners.
A new form of the virus has triggered global concern as it seems to spread easily though routine close contact, prompting the health agencyto declare mpox a global public health emergency earlier thismonth.
Sweden and Thailand have confirmed cases of the clade Ib type of the virus, outside of the Democratic Republic of Congo and neighboring countries.
With as many as 1,000 suspected cases reported in the Congo alone this week, the need for diagnostic tests has surged dramatically, the agencysaid.
In the coming weeks, it will deliver another 30,000 tests to African countries.
The WHOhas also updated its diagnostic testing guidance to detect the new virus strain and is working with counties to roll it out.
Manufacturers of in-vitrodiagnostics have been asked to provide available data on the quality, safety and performance of the tests to the WHO as soon as possible.
Earlier this week, diagnostics firm Labcorp LH.N said it is working with U.S. health regulators to determine if it needed to ramp up its mpox testing capacity.
Swiss drugmaker Roche ROG.S is actively working to enhance laboratory testing capacity for mpox worldwide.
Reporting by Sriparna Roy in Bengaluru; Editing by Mohammed Safi Shamsi and Arun Koyyur
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
